Capsules (on 5 pieces in blister strip packagings, on 4 packagings in a cardboard pack; on 6 pieces in blister strip packagings, on 5 packagings in a cardboard pack; on 7 pieces in blister strip packagings, on 2 packagings in a cardboard pack; on 10 pieces in blister strip packagings, on 1-5 packagings in a cardboard pack; on 30 pieces in blister strip packagings, on 1-4 packagings in a cardboard pack; on 10, 20, 30, 40, 50, 100 pieces in banks, after 1 bank in a cardboard pack);
Tablets of the prolonged action, film coated (on 10 pieces in blisters, on 2, 3, 6 blisters in a cardboard pack; on 30 pieces in banks, after 1 bank in a cardboard pack);
Tablets with the modified release, coated (on 10 and 14 pieces in blister strip packagings, on 1, 2, 3, 100, 200, 300, 400, 500 packagings in a cardboard pack);
Tablets, coated (on 20, 30 pieces in polyethylene bottles or banks, on 1 bottle or bank in a cardboard pack; on 10, 20, 30 pieces in blister strip packagings, on 1-6, 8, 10, 20, 40, 60, 80, 100 packagings in a cardboard pack; on 10 pieces in polymeric containers, on 1, 10, 20, 30, 40, 50, 100 containers in a cardboard pack; on 20, 30, 40, 50 pieces in polymeric containers, on 1, 10, 20 containers in a cardboard box);
Tablets, film coated (on 10, 20 pieces in blisters, on 1-5 blisters in a cardboard pack; on 30, 50 pieces in blister strip packagings, on 1-3 packagings in a cardboard pack; on 10, 20, 25, 30, 50, 500, 1000 pieces in a polyethylene bottle, on 1 bottle in a cardboard pack).

Active agent – индапамид is a part of drug:

Tablets of the prolonged action and tablet with the modified release, coated – 1,5 mg;
Capsules, tablets, coated, and tablets, film coated – 2,5 mg.

Auxiliary components:

Capsules: microcrystallic cellulose, magnesium stearate;
Tablets of the prolonged action, film coated: monohydrate of lactose, gipromelloz, magnesium stearate, anhydrous colloid silicon dioxide;
Tablets, coated: polyethyleneglycol, monohydrate of lactose (Toure 312), monohydrate of lactose (Spray-Dried), microcrystallic cellulose, magnesium stearate, croscarmellose sodium;
Tablets, film coated: monohydrate of lactose, K30 povidone, кросповидон, magnesium stearate, sodium lauryl sulfate, talc.

Indications to use

Indapamid appoint for treatment of arterial hypertension.

Contraindications

Heavy renal failure (in an anury stage);
The expressed liver failure (including with encephalopathy);
Galactosemia;
Hypopotassemia;
Syndrome of disturbance of absorption of a glucose/galactose, lactose intolerance;
Concomitant use with the drugs extending QT interval;
Pregnancy and period of a lactation;
Age up to 18 years (safety and efficiency of use of drug for this age group of patients are not established);
Hypersensitivity to drug components, and also to other derivatives of sulfonamide.

Indapamid patients should take with caution with functional disturbances of kidneys and/or a liver, a diabetes mellitus in a decompensation stage, a hyperuricemia (especially, followed uratny nephrolithiasis and gout), disturbances of water and electrolytic balance, a hyperparathyreosis, with the increased QT interval on an ECG or receiving other antiarrhytmic drugs.

Route of administration and dosage

Indapamid accept inside, once, in the morning, without chewing and washing down with liquid in enough.

Daily dose of drug – 1 tablet (in the form of tablets of the prolonged action and tablets with the modified release, coated – 1,5 mg; capsules, tablets, coated, and tablets, film coated – 2,5 mg). If in 1-2 months of therapy the desirable therapeutic effect is not reached, Indapamid's dose is not recommended to be increased (because of increase of risk of development of side effects without strengthening of anti-hypertensive effect). In these cases it is necessary to include other anti-hypertensive medicine which is not diuretic in the scheme of drug treatment. At reception of two various drugs, Indapamid's dose should not be adjusted (1 tablet a day, once, in the morning).

Side effects

During Indapamid's reception development of disturbances from some systems of an organism is possible:

Cardiovascular system: orthostatic hypotension, arrhythmia, changes on an ECG (hypopotassemia), heartbeat;
Central nervous system: nervousness, adynamy, headache, drowsiness, dizziness, sleeplessness, вертиго, depression; seldom – an indisposition, the general weakness, increased fatigue, a spasm of muscles, irritability, tension, alarm;
Alimentary system: an abdominal pain, nausea, dryness in a mouth, anorexia, vomiting, a gastralgia, diarrhea, a lock, development of hepatic encephalopathy is possible; seldom – pancreatitis;
Urinary system: nocturia, frequent infections, polyuria;
Respiratory system: sinusitis, pharyngitis, cough; seldom – rhinitis;
System of a hemopoiesis: very seldom – a leukopenia, thrombocytopenia, an agranulocytosis, hemolitic anemia and an aplasia of marrow;
Laboratory indicators: a hypercalcemia, a hyperuricemia, a hypopotassemia, a hyperglycemia, a hyponatremia, a hypochloraemia, increase in an urea nitrogen in a blood plasma, a glucosuria, a giperkreatininemiya;
Allergic reactions: hemorrhagic vasculitis, small tortoiseshell, rash, itch;
Others: aggravation of a current of a system lupus erythematosus.

Special instructions

The elderly patients and patients accepting purgatives and cardiac glycosides against the background of a hyper aldosteronism need to control the maintenance of potassium ions and creatinine regularly.

During therapy it is necessary to control systematically concentration of ions of sodium, magnesium and potassium in a blood plasma (because of possible electrolytic disturbances), рН, concentration of glucose, residual nitrogen and uric acid. The first research of potassium concentration in blood is conducted during the first 7 days of treatment.

Also patients with the increased QT interval on the ECG (which developed against the background of any pathological process or inborn) treat group of the increased risk.

Patients with cirrhosis (especially with ascites or hypostases that is connected with risk of development of the metabolic alkalosis increasing expressiveness of hepatic encephalopathy), heart failure, coronary heart disease, and also patients of advanced age need the most careful control.

The hypercalcemia which developed in time of use of Indapamid can demonstrate existence of the hyperparathyreosis which is not diagnosed earlier.

It is necessary to control glucose level in blood at patients with a diabetes mellitus, especially at a hypopotassemia.

Considerable dehydration can lead to developing of an acute renal failure (decrease in glomerular filtering). Patients should offset loss of water and at the beginning of therapy carefully to control function of kidneys.

When carrying out a drug test Indapamid can yield a positive take.

At the arterial hypertension and a hyponatremia (connected with reception of diuretics) it is necessary in 3 days prior to reception of inhibitors of an angiotensin-converting enzyme to interrupt reception of diuretics (in case of need a bit later reception of diuretics can be resumed), or to appoint initial inhibitors of an angiotensin-converting enzyme in low doses.

Derivatives of sulfonamides can cause an aggravation of a current of a system lupus erythematosus (it is necessary to consider at Indapamid's appointment).

In some cases during therapy individual reactions which are connected with change of arterial pressure, especially at the beginning of therapy and at addition of other anti-hypertensive drug are possible. Because of it ability to driving and performance of the works requiring special attention can go down.

Medicinal interaction

At simultaneous use of Indapamid with some medicines there can be undesirable effects:

Saluretics, purgatives, cardiac glycosides, тетракозактид, glyuko-and mineralokortikoida, Amphotericinum In (intravenously): increase in risk of development of a hypopotassemia;
Cardiac glycosides: increase in probability of development of digitalis intoxication;
Erythromycin (intravenously), астемизол, pentamidine, Vincaminum, терфенадин, сультоприд, antiarrhytmic means of I A classes (Disopyramidum, quinidine) and III class (bretylium tosylate, Amiodaronum, соталол): development of arrhythmia in the pirouette type (torsades de pointes);
Non-steroidal anti-inflammatory drugs, тетракозактид, glucocorticosteroids, sympathomimetics: decrease in hypotensive effect;
Calcium drugs: increase in probability of development of a hypercalcemia;
Neuroleptics and imipraminovy (tricyclic) antidepressants: strengthening of hypotensive action and increase in risk of development of orthostatic hypotension;
Cyclosporine: increase in risk of development of a giperkreatininemiya;
Metforminum: increase in probability of aggravation of lactic acidosis;
Inhibitors of an angiotensin-converting enzyme: increase in risk of development of an acute renal failure and/or arterial hypotension (especially at the available renal artery stenosis);
Iodinated contrast means in high doses: increase in risk of development of renal failures (organism dehydration is possible, before use of iodinated substances by the patient it is necessary to recover liquid loss);
Baclofenum: strengthening of hypotensive effect;
Kaliysberegayushchy diuretics: development hyper - or hypopotassemias, especially at patients with a renal failure and a diabetes mellitus (some category of patients can have effective such combination);
Indirect anticoagulants (derivatives of an indandion or coumarin): decrease in their effect (dose adjustment can be required);
Not depolarizing muscle relaxants: strengthening of blockade of the neuromuscular transmission developing under their action.

Indapamid increases concentration in a blood plasma of ions of lithium (decrease in removal with urine), lithium has nephrotoxic effect.

Terms and storage conditions

To store in dry, protected from light, the place, unavailable to children.

Period of validity:

Capsules, tablets of the prolonged action, film coated, tablets with the modified release, coated – 2 years at a temperature up to 25 °C;
Tablets, coated – 3 years at a temperature of 15-30 °C;
Tablets, film coated – 4 years at a temperature of 15-25 °C.

The prices in Internet drugstores:

Name of drug

Price

Drugstore

Indapamid of piece tablet 2,5mg 30

18 rub.

To buy